30 May '16
Viriom, a biomedical developer and asset of the ChemRar High Tech Center in Khimki outside Moscow, has been working on Russia’s first HIV solution which is expected to go beyond import substitution—an across-the-board goal the Russians have been pursuing in many sectors since the current crisis and western sanctions began—and offer “high potential for international commercialization.”
The new drug candidate’s safety, high efficacy and tolerance are said to have been proven during five rounds of phases 1 and 2 clinical trial testing. Phase 3 of clinical trials is currently under way in 18 AIDS prevention centers across Russia.
The Skolkovo Foundation, which is managing Russia’s most widely touted innovation hub just outside Moscow, earlier this year approved a new $2.2m grant for the next stage of the effort.